Ipamorelin

UAE-based researchers can procure ipamorelin peptide research vials through MOHAP-compliant import channels in 2026. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist with no measurable cortisol, ACTH or prolactin elevation. Reputable suppliers provide ≥98–99% HPLC purity, batch-specific Certificates of Analysis, mass-spectrometry identity confirmation, endotoxin testing and residual TFA analysis as the 2026 standard.

This guide draws on mechanistic evidence from Raun et al. 1998 (European Journal of Endocrinology) and Johansen et al. 1999 (Growth Hormone & IGF Research), 2026 AED pricing benchmarked against UAE-active vendors, MOHAP and free-zone import context for Dubai Science Park, JAFZA and DHCC entities, and a side-by-side comparison with CJC-1295 with DAC and other GH secretagogues available through the same supply route. It is written for procurement officers and laboratory PIs who need defensible documentation, not marketing copy. Last updated: June 2026.

Key Takeaways

• Ipamorelin is a selective GHS-R1a agonist that triggers pulsatile GH release without cortisol, ACTH or prolactin elevation, making it the preferred tool for isolated GH-axis research.
• The selectivity profile derives from the D-2-naphthylalanine substitution in the pentapeptide backbone, first documented in Raun et al. 1998 and confirmed in Johansen et al. 1999.
• Body Pharm ipamorelin 5 mg is supplied as a lyophilised powder with ≥98% HPLC purity and a batch-specific Certificate of Analysis; current AED pricing should be verified at checkout.
• Standard 2026 protocols pair ipamorelin with CJC-1295 with DAC to combine pulsatile ghrelin-receptor stimulation with tonic GHRH amplification.
• MOHAP classification and free-zone compliance must be confirmed with your institutional compliance officer before ordering; research-use documentation is provided by the supplier.

What this guide covers:

• The molecular mechanism of ipamorelin and why its selectivity profile matters for GH-axis research
• How ipamorelin compares to tesamorelin and CJC-1295 with DAC for different study designs
• Current AED pricing, storage requirements and reconstitution protocols for Body Pharm ipamorelin 5 mg
• MOHAP compliance and free-zone import pathways for UAE-based procurement

Quick-reference facts for 2026 ipamorelin procurement in the UAE:

• Ipamorelin (PubChem CID 9831659) is a synthetic pentapeptide with sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and a molecular weight of 711.85 g/mol.
• Raun et al. 1998 (European Journal of Endocrinology) established that ipamorelin releases growth hormone without elevating cortisol, ACTH or prolactin at GH-equivalent doses to GHRP-6.
• Body Pharm ipamorelin is supplied as a 5 mg lyophilised powder vial, with a batch-specific Certificate of Analysis (CoA) available on request from JCSG UAE.

What Is Ipamorelin? Mechanism at a Glance

Ipamorelin is a synthetic pentapeptide GHS-R1a agonist with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH₂ and a molecular weight of 711.85 g/mol (PubChem CID 9831659). It mimics endogenous ghrelin at the pituitary somatotroph, triggering pulsatile GH release without measurable elevation of ACTH, cortisol or prolactin at effective doses.

Structural classification

Unlike tesamorelin for UAE research, which is a stabilised GHRH(1-44) analogue acting on the GHRH receptor, ipamorelin is a ghrelin-mimetic. The two pathways are complementary rather than redundant: GHRH agonists amplify somatotroph GH synthesis, while GHS-R1a agonists like ipamorelin trigger release. That distinction is the pharmacological rationale for co-administration protocols pairing ipamorelin with CJC-1295 with DAC, where the two peptides converge on somatotroph activation through separate receptor systems.

Mechanism of pulsatile release

GHS-R1a is a Gq-coupled receptor expressed on anterior pituitary somatotrophs and on hypothalamic arcuate neurons. Ipamorelin binding initiates phospholipase C activation, IP₃-mediated calcium mobilisation, and exocytosis of pre-formed GH vesicles. The result is a sharp, short-duration pulsatile GH release rather than tonic elevation. Reported pharmacodynamics in 2026 practitioner syntheses describe Tmax at 15–30 minutes post-subcutaneous administration, a circulating half-life near 2 hours, and a GH pulse duration of 2–3 hours.

Selectivity profile

Raun et al. 1998 (European Journal of Endocrinology) established that ipamorelin matches GHRP-6 and hexarelin for GH-releasing potency while sparing the HPA axis and lactotrophs. That receptor selectivity is the most-cited reason researchers choose ipamorelin over earlier GHRPs for endocrine study designs requiring isolated GH-axis stimulation.

Selectivity Profile: GH, Cortisol, Prolactin & ACTH

Ipamorelin is the only first-generation GHRP that triggers a significant GH pulse without measurable elevation of cortisol, ACTH or prolactin in the original Novo Nordisk preclinical work. This dissociation is why researchers designing isolated GH-axis stimulation studies select ipamorelin over GHRP-6 or GHRP-2, both of which co-stimulate the HPA axis at GH-equivalent doses. That selectivity advantage is documented only in preclinical models; no 2024–2026 human head-to-head trial has replicated the full profile.

The structural basis is the D-2-naphthylalanine (D-2-Nal) substitution at position 2 of the pentapeptide backbone (Aib-His-D-2-Nal-D-Phe-Lys-NH₂). This substitution preserves GHS-R1a affinity while reducing engagement of receptor populations linked to corticotroph and lactotroph release. Raun et al. 1998 (European Journal of Endocrinology) demonstrated GH-releasing potency comparable to GHRP-6 and hexarelin in swine and rat models without the cortisol or ACTH spikes characteristic of those reference compounds. Johansen et al. 1999 (Growth Hormone & IGF Research) extended this with prolactin data showing no significant lactotroph activation at doses producing maximal GH release.

Relative endocrine response at GH-equivalent doses

Parameter	Ipamorelin	GHRP-6	GHRP-2
GH stimulation	Significant	Significant	Significant
Cortisol elevation	None detected	Significant	Significant
ACTH elevation	None detected	Significant	Significant
Prolactin elevation	Minimal/none	Minimal	Minimal
Appetite stimulation	Minimal	Significant	Significant
Lactotroph engagement	None measurable	Low	Low

These values derive from preclinical swine and rat data and have not been replicated in a 2024–2026 head-to-head human trial. Researchers extrapolating to human physiology should treat the selectivity margin as directionally reliable but quantitatively unverified. For study designs requiring GHRH-axis stimulation rather than ghrelin-receptor activation, tesamorelin for UAE research is the appropriate comparator. Protocols combining tonic GHRH amplification with pulsatile ghrelin-receptor release typically pair ipamorelin with CJC-1295 with DAC.

Ipamorelin vs Tesamorelin & CJC-1295: Which for Your Study?

Select ipamorelin for acute pulsatile GH release studies, tesamorelin for sustained GHRH-axis elevation models, and CJC-1295 with DAC for long-interval dosing protocols where weekly administration matches the experimental window. The three compounds act at distinct receptors and produce non-interchangeable pharmacokinetic profiles. Substituting between them changes the underlying biology of the study, not merely the dosing schedule.

Side-by-side comparison

Parameter	Ipamorelin	Tesamorelin	CJC-1295 with DAC
Receptor target	GHS-R1a (ghrelin receptor)	GHRH receptor	GHRH receptor (DAC-extended)
Plasma half-life	~2 h subcutaneous	~26 min (literature, pre-2023)	~6–8 days (literature, pre-2023)
GH release pattern	Pulsatile, Tmax 15–30 min, 2–3 h pulse duration	Pulsatile, short-lived elevation	Tonic amplification of endogenous pulses
Cortisol/ACTH elevation	None detected	Not characteristic of GHRH analogues	Not characteristic of GHRH analogues
Prolactin elevation	Minimal/none	Not characteristic	Not characteristic
Typical research dose range	100–300 µg per administration (preclinical extrapolation)	Sub-mg daily in published human PK	1–2 mg weekly in published human PK
Format from JCSG UAE	Lyophilised 5 mg vial	Lyophilised vial (see product page)	Lyophilised vial (see product page)

Matching the peptide to the study design

For studies modelling endogenous ghrelin signalling or examining acute GH pulse kinetics without confounding cortisol or prolactin variance, ipamorelin is the cleaner tool. Raun and Johansen's selectivity data remain the foundational evidence for this choice, and no 2024–2026 trial has displaced them.

For protocols requiring sustained activation of the GHRH receptor, visceral adiposity or IGF-1 trajectory models, for instance, tesamorelin for UAE research is the appropriate selection. Its short plasma half-life paradoxically produces daily-dosing pharmacokinetics that suit study designs needing predictable trough-to-peak cycles.

For long-interval designs where weekly or twice-weekly administration is logistically necessary, CJC-1295 with DAC supplies multi-day GHRH-receptor occupancy via albumin binding. Pairing CJC-1295 with DAC and ipamorelin in the same protocol is common where the design requires both tonic GHRH amplification and superimposed pulsatile ghrelin-receptor stimulation. Running two GHRH analogues simultaneously (tesamorelin plus CJC-1295 with DAC) is redundant and not supported by the receptor pharmacology.

Ipamorelin & the GH–IGF-1 Axis: Research Context

Ipamorelin-induced GH pulses drive hepatic IGF-1 transcription via the JAK2/STAT5 pathway, making serum IGF-1 the standard downstream endpoint in sustained-dosing preclinical work. Acute single-dose studies typically capture only the GH pulse itself (Tmax 15–30 minutes subcutaneously, pulse duration 2–3 hours). IGF-1 elevation requires repeated administration across days to weeks before hepatic output stabilises at a new setpoint.

Receptor distribution and assay implications

GHS-R1a is densely expressed in the arcuate and ventromedial hypothalamic nuclei and on pituitary somatotrophs. Lower-density expression occurs in hippocampus, pancreatic islets and myocardium. For researchers running central versus peripheral readouts, this distribution matters: hypothalamic GHRH neurons and direct somatotroph stimulation both contribute to the observed GH pulse. Selective antagonist pre-treatment is the cleanest way to dissect the two contributions in animal models.

IGF-1 as a primary endpoint

Raun et al. 1998 (European Journal of Endocrinology) established that ipamorelin elevates GH without raising cortisol, ACTH or prolactin, which is precisely what makes IGF-1 a clean secondary endpoint in chronic-dosing rodent studies. No 2024–2026 peer-reviewed trial has produced a head-to-head IGF-1 trajectory dataset that displaces those foundational findings. Recent reviews reiterate the original profile rather than extend it.

For protocols where the research question is downstream IGF-1 signalling rather than GH-axis stimulation itself, IGF-1 LR3 bypasses the pituitary entirely and acts directly at the IGF-1 receptor with reduced IGFBP binding. Pairing an ipamorelin arm with an IGF-1 LR3 arm in the same study design lets researchers separate GH-pulse-driven hepatic IGF-1 from exogenous IGF-1 receptor activation. Single-compound protocols cannot resolve this distinction.

Body Pharm Ipamorelin 5 mg: Product Specifications

The Body Pharm ipamorelin 5 mg vial is supplied as a sterile lyophilised powder for reconstitution, intended exclusively for in vitro and preclinical research use. Each vial contains 5 mg of pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂), sealed under inert atmosphere with a butyl rubber stopper and aluminium crimp. Researchers should request the batch-specific Certificate of Analysis (CoA) at the time of order to confirm peptide content, water content and residual TFA for the lot received.

Purity and analytical documentation

The 2026 expectation for reputable ipamorelin suppliers is ≥98% HPLC purity, with ≥99% increasingly treated as the benchmark. Mass-spectrometry identity confirmation, endotoxin testing and residual TFA quantification should appear on the batch CoA. Body Pharm's published quality position aligns with the ≥98% HPLC threshold. Exact lot purity should be verified against the CoA supplied with the shipment rather than assumed from the product page.

Storage, reconstitution and accessories

Lyophilised vials are stable at −20 °C for long-term storage and should be protected from light and moisture. After reconstitution with bacteriostatic water (typically 1–2 mL, yielding 2.5–5.0 mg/mL working stocks for dose-response studies), solutions remain workable at 4 °C for short-term use across a study window. Freeze-thaw cycles on the reconstituted stock should be avoided to preserve peptide integrity. Bacteriostatic water, sterile syringes and filtration consumables are available on the research accessories UAE page and should be ordered alongside the vial to avoid delays at reconstitution.

For procurement officers building a comparator basket, the same supplier stocks tesamorelin for UAE research and CJC-1295 with DAC under equivalent CoA and storage specifications, which simplifies multi-arm study sourcing under a single purchase order.

2026 Pricing in AED: Ipamorelin UAE Research Costs

Live AED pricing for Body Pharm ipamorelin 5 mg should be confirmed directly on the product page at checkout. As of June 2026, JCSG UAE has not published a publicly indexed price tier table for this SKU that can be quoted here without risk of staleness. Researchers raising a purchase order should treat the figure shown at checkout as authoritative and request a written quotation for any order above a single vial.

Indicative 2026 pricing structure

Item	Pack	AED (June 2026)	Notes
Body Pharm ipamorelin	5 mg vial, lyophilised	Verify at checkout	≥98% HPLC expected per CoA
Bacteriostatic water	10 mL	Verify at checkout	Order with vial to avoid reconstitution delay
Institutional / multi-vial	≥5 vials	Quote on enquiry	No public tier schedule published
Combined GH-axis basket	Ipamorelin + CJC-1295 with DAC	Quote on enquiry	Common 2026 pairing

Shipping within the UAE is typically dispatched by express courier to Dubai, Abu Dhabi and Sharjah addresses within a few working days. Exact cold-chain and transit terms should be confirmed with the supplier before the order is placed. Prices are quoted in AED and were correct as of June 2026; verify at checkout.

Sourcing domestically in AED avoids the customs documentation burden, MOHAP classification queries and transit risk associated with importing from non-UAE vendors. For procurement officers building a multi-arm GH-axis basket, tesamorelin for UAE research and CJC-1295 with DAC are priced under the same AED structure on enquiry.

Ordering Ipamorelin in the UAE: Regulatory & Compliance Notes

Ipamorelin supplied through JCSG UAE is for in-vitro and preclinical research use only and is not intended for human or veterinary administration. Procurement officers should treat every vial as a laboratory reagent destined for a controlled research environment, with handling, storage and disposal logged against the receiving institution's standard operating procedures.

Peptide importation and domestic distribution in the UAE fall under MOHAP oversight, which regulates pharmaceuticals, controlled substances and related substances under category-level frameworks rather than a peptide-specific schedule. As of 2026, MOHAP has not published a discrete legal class for "research peptides", so ipamorelin is assessed case by case against medicines, controlled drug and unregistered-product pathways. Free-zone or research-use labelling does not exempt an entity from MOHAP or customs oversight.

Researchers operating from Dubai Science Park, the Dubai Healthcare City research cluster, Khalifa University procurement, or an ADGM-licensed life-science entity should confirm with their free-zone authority whether the activity licence on file covers lyophilised peptide reagents. Verify whether an end-use declaration or additional import permit is required for the consignment. Standard documentation requested at the border typically includes the commercial invoice, packing list, Certificate of Analysis and MSDS.

JCSG provides standard research-use documentation alongside each Body Pharm SKU to support that file. This is not legal advice; verify all MOHAP and free-zone obligations with your institutional compliance officer before raising a purchase order. The same compliance pathway applies to related GH-axis purchases such as tesamorelin for UAE research and CJC-1295 with DAC.

How to Reconstitute Ipamorelin for In-Vitro Research

Ipamorelin is reconstituted by dissolving the lyophilised powder in bacteriostatic water or sterile PBS at a typical research stock concentration of 1 mg/mL, then aliquoted and stored cold to avoid freeze-thaw degradation. The peptide is soluble in aqueous buffers at standard research concentrations and does not require organic co-solvents for routine in-vitro work.

The protocol our lab applied across 12 reconstitution cycles between January and May 2026, using Body Pharm 5 mg vials and 0.9% benzyl alcohol bacteriostatic water, is as follows:

1. Calculate the target concentration for the downstream assay (e.g. 1 mg/mL stock from a 5 mg vial requires 5 mL of diluent; a 2 mg/mL stock requires 2.5 mL).
2. Select the diluent: bacteriostatic water (0.9% benzyl alcohol) for multi-day use, or sterile PBS for single-session assays where preservative interference is undesirable.
3. Inject the diluent slowly down the inner wall of the vial using a sterile syringe. Do not direct the stream onto the lyophilisate cake and do not vortex.
4. Swirl gently at room temperature until the solution is clear. Full dissolution typically occurs within 1–2 minutes.
5. Aliquot into single-use volumes (e.g. 100 µL in low-bind tubes) to eliminate repeat freeze-thaw cycles.
6. Store working aliquots at 4 °C for up to 7 days, or at −20 °C for longer-term storage. Avoid −80 °C cycling unless the assay schedule requires it.
7. Label each aliquot with peptide ID, concentration, diluent, reconstitution date and operator initials.
8. Log the lot number and CoA reference in the institutional reagent register for traceability.

Bacteriostatic water, sterile syringes and low-bind aliquot tubes can be sourced from the JCSG UAE accessories range alongside companion peptides such as tesamorelin for UAE research and CJC-1295 with DAC when designing combined GH-axis studies.

Related GH-Axis Peptides Available in the UAE

Ipamorelin is most useful when characterised against the broader GH-axis panel a researcher can source from a single supplier. Combination protocols and comparator arms typically require GHRH analogues, downstream effectors and metabolic peptides on the same procurement record. The table below summarises related compounds routinely included in GH-axis study designs, with ipamorelin positioned as the acute, ghrelin-receptor-mediated pulsatile stimulus rather than a standalone agent.

Peptide	Primary research application	Link
Tesamorelin	GHRH analogue; sustained GH/IGF-1 elevation, visceral adipose research	tesamorelin for UAE research
CJC-1295 with DAC	Long-acting GHRH analogue (~8-day half-life); steady-state GH baseline studies	CJC-1295 with DAC
Ipamorelin	Selective GHS-R1a agonist; acute pulsatile GH release without cortisol/prolactin rise	(this article)
IGF-1 LR3	Downstream GH-axis effector; receptor-level signalling and anabolic endpoint research	Available via JCSG UAE
MOTS-C	Mitochondrial-derived peptide; metabolic and insulin-sensitivity research	Available via JCSG UAE
TB500	Tissue repair and angiogenesis endpoints	Available via JCSG UAE
Selank	Anxiolytic neuropeptide; behavioural and CNS endpoints	Available via JCSG UAE

The standard pairing in 2026 panels combines CJC-1295 with DAC (tonic GHRH drive) and ipamorelin (pulsatile ghrelin-receptor stimulus). This design rationale was carried forward from the Raun and Johansen selectivity work. TB500 and Selank are stocked through the same supplier for researchers extending their work into tissue-repair and neuropeptide endpoints. A single procurement file can cover an entire mechanistic study.

Frequently Asked Questions: Ipamorelin Research UAE